first_imgEfforts to Copy Biotech Drugs Face Delays, Obstacles The Wall Street Journal: Biotech Drugs Still Won’t CopyMuch anticipated knockoff versions of costly biotech medicines are facing delays and obstacles that could cost patients and health systems billions in missed savings (Weaver, Whalen and Rockoff, 2/26). This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.last_img